These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 36401022)

  • 21. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.
    Komaki H; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y; Takeda S
    Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
    Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Casimersen for Duchenne muscular dystrophy.
    Wilton-Clark H; Yokota T
    Drugs Today (Barc); 2021 Dec; 57(12):707-717. PubMed ID: 34909800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies.
    Sheikh O; Yokota T
    Expert Opin Investig Drugs; 2021 Feb; 30(2):167-176. PubMed ID: 33393390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Restoring Dystrophin Expression by Skipping Exons 6 and 8 in Neonatal Dystrophic Dogs.
    Shah MNA; Yokota T
    Methods Mol Biol; 2023; 2587():107-124. PubMed ID: 36401026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update.
    Sheikh O; Yokota T
    Arch Toxicol; 2022 Jan; 96(1):1-9. PubMed ID: 34797383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
    JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.
    Echigoya Y; Lim KRQ; Melo D; Bao B; Trieu N; Mizobe Y; Maruyama R; Mamchaoui K; Tanihata J; Aoki Y; Takeda S; Mouly V; Duddy W; Yokota T
    Mol Ther; 2019 Nov; 27(11):2005-2017. PubMed ID: 31416775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient.
    Saito T; Nakamura A; Aoki Y; Yokota T; Okada T; Osawa M; Takeda S
    PLoS One; 2010 Aug; 5(8):e12239. PubMed ID: 20805873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy.
    Dzierlega K; Yokota T
    Gene Ther; 2020 Sep; 27(9):407-416. PubMed ID: 32483212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment.
    Negishi Y; Ishii Y; Nirasawa K; Sasaki E; Endo-Takahashi Y; Suzuki R; Maruyama K
    Methods Mol Biol; 2018; 1687():185-192. PubMed ID: 29067664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A
    Echigoya Y; Trieu N; Duddy W; Moulton HM; Yin H; Partridge TA; Hoffman EP; Kornegay JN; Rohret FA; Rogers CS; Yokota T
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ; Malerba A; Dickson G
    Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eteplirsen in the treatment of Duchenne muscular dystrophy.
    Lim KR; Maruyama R; Yokota T
    Drug Des Devel Ther; 2017; 11():533-545. PubMed ID: 28280301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy.
    Benny Klimek ME; Vila MC; Edwards K; Boehler J; Novak J; Zhang A; Van der Meulen J; Tatum K; Quinn J; Fiorillo A; Burki U; Straub V; Lu QL; Hathout Y; van Den Anker J; Partridge TA; Morales M; Hoffman E; Nagaraju K
    J Neuromuscul Dis; 2021; 8(s2):S369-S381. PubMed ID: 34569970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Exon skipping therapy for Duchenne muscular dystrophy by using antisense Morpholino].
    Takeda S
    Rinsho Shinkeigaku; 2009 Nov; 49(11):856-8. PubMed ID: 20030230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.
    Echigoya Y; Nakamura A; Nagata T; Urasawa N; Lim KRQ; Trieu N; Panesar D; Kuraoka M; Moulton HM; Saito T; Aoki Y; Iversen P; Sazani P; Kole R; Maruyama R; Partridge T; Takeda S; Yokota T
    Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4213-4218. PubMed ID: 28373570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy.
    Watanabe N; Nagata T; Satou Y; Masuda S; Saito T; Kitagawa H; Komaki H; Takagaki K; Takeda S
    Mol Ther Nucleic Acids; 2018 Dec; 13():442-449. PubMed ID: 30388618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eteplirsen: First Global Approval.
    Syed YY
    Drugs; 2016 Nov; 76(17):1699-1704. PubMed ID: 27807823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy.
    Yokota T; Hoffman E; Takeda S
    Methods Mol Biol; 2011; 709():299-312. PubMed ID: 21194037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.